SCHEMBL5544010

SCHEMBL5544010

Cc1nc(-c2cccc(Cl)c2)c(C)o1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.53
PTGS2 P35354 1/20 0.53
ALDH1A1 P00352 2/20 0.46
CYP1A2 P05177 1/20 0.46
NPC1 O15118 2/20 0.45
TP53 P04637 2/20 0.45
RAB9A P51151 2/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPY5R Q15761 1/20 0.43
ADORA2A P29274 2/20 0.43
ADORA1 P30542 2/20 0.43
NOTUM Q6P988 1/20 0.43
ADORA2B P29275 1/20 0.43
MAPT P10636 1/20 0.42
GPBAR1 Q8TDU6 1/20 0.41
ESR2 Q92731 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5538640 0.86 PTGS1 (0.53) PTGS1PTGS2ALDH1A1CYP1A2NPC1
SCHEMBL5544005 0.83 PTGS1 (0.50) PTGS1PTGS2ALDH1A1CYP1A2NPC1
SCHEMBL10263008 0.82 RAB9A (0.47) ALDH1A1NPC1TP53RAB9ATSHR
SCHEMBL10833110 0.80 PTGS1 (0.43) PTGS1PTGS2ALDH1A1CYP1A2NPC1
SCHEMBL5541456 0.79 ADORA2A (0.46) ADORA2AADORA1NOTUMADORA2BMAPT
SCHEMBL5536993 0.78 ALDH1A1 (0.47) PTGS1PTGS2ALDH1A1NPC1RAB9A
SCHEMBL5214925 0.77 MAPK13 (0.58) PTGS1PTGS2ALDH1A1TP53RAB9A
SCHEMBL5546758 0.76 ALDH1A1 (0.48) PTGS1PTGS2ALDH1A1CYP1A2NPC1
SCHEMBL10832209 0.76 ADORA2A (0.47) ALDH1A1CYP1A2NPC1RAB9ASMN1; SMN2
SCHEMBL10834272 0.74 RXRA (0.44) PTGS1PTGS2ALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
WO-2012085852-A1 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES ACTELION PHARMACEUTICALS LTD (CH) 2012-06-28 WO disclosed
WO-2012085857-A1 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES ACTELION PHARMACEUTICALS LTD (CH) 2012-06-28 WO disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
US-4596816-A Pharmaceuticals TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1986-06-24 US disclosed
EP-0092239-A2 Oxazole derivatives, production and use thereof Takeda Chemical Industries, Ltd. (JP) 1983-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PTGS1 3838/4885PTGS2 3418/4885ALDH1A1 355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.